MIRA Pharmaceuticals (NASDAQ:MIRA) Releases Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.03) EPS for the quarter, FiscalAI reports.

MIRA Pharmaceuticals Stock Down 4.4%

Shares of NASDAQ:MIRA traded down $0.03 during midday trading on Monday, reaching $0.63. The company’s stock had a trading volume of 58,263 shares, compared to its average volume of 268,305. The firm has a 50 day moving average of $0.70 and a 200-day moving average of $0.93. The firm has a market capitalization of $26.52 million, a P/E ratio of -0.51 and a beta of 1.65. MIRA Pharmaceuticals has a 12-month low of $0.51 and a 12-month high of $1.69.

Institutional Investors Weigh In On MIRA Pharmaceuticals

An institutional investor recently bought a new position in MIRA Pharmaceuticals stock. BlackRock Inc. purchased a new position in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 244,622 shares of the company’s stock, valued at approximately $232,000. BlackRock Inc. owned approximately 0.58% of MIRA Pharmaceuticals as of its most recent SEC filing. Institutional investors own 35.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MIRA shares. Weiss Ratings raised MIRA Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 2nd. Maxim Group began coverage on shares of MIRA Pharmaceuticals in a report on Thursday, September 17th. They set a “buy” rating and a $3.50 target price for the company. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $3.50.

Read Our Latest Stock Analysis on MIRA

MIRA Pharmaceuticals Company Profile

(Get Free Report)

MIRA Pharmaceuticals is a clinical-stage pharmaceutical company developing oral drug candidates for neurological and neuropsychiatric conditions. Its pipeline includes MIRA1a, an investigational synthetic cannabinoid analog being studied for potential use in conditions such as anxiety and chronic pain. The company has also added Ketamir-2, an investigational oral ketamine analog being developed for potential treatment of depression and neuropathic pain. These candidates remain in development and are not approved medicines.

Featured Stories

Earnings History for MIRA Pharmaceuticals (NASDAQ:MIRA)

Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.